StockIQStockIQ.tech

GE HealthCare Technologies Inc. (GEHC) Stock Analysis

--

Free AI-powered analysis and research for GE HealthCare Technologies Inc. stock

Sector: Healthcare

GEHC snapshot

Data as of 3 Nov 2026 close. Updated daily.

Last close
79.76 USD (+0.27%)
52-week range
58.75 – 89.77
Position in range
68%
1-year change
+7.1%
Market cap (USD)
$36.1B
P/E (trailing)
16.2
RSI (14-day)
79
vs 200-day average
+14.3%
MACD
Above signal line
StockIQ score: 81/100 · Strongly positive signals

GE HealthCare Technologies Inc. scores 81/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 68% of its 52-week range, up 7.1% over the past year. Latest reported figures show a profit margin of 10.0%, return on equity of 20.0% and revenue growth of +7.2%.

What is driving the score
  • Strong Uptrend: +12
  • MACD Bullish: +8
  • Weak Liquidity (1.30 Current Ratio): -5
  • Excellent ROE (20.0%): +8
  • Strong Long-term Uptrend: +8
  • Up Over 1 Year (+7.1%): +3
  • Low Volume (0.5x): -3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full GEHC report

GE HealthCare Technologies Inc. (GEHC) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze GEHC Now →

📰 Latest Update

GE HealthCare Technologies Q3 Earnings Call Highlights

GE HealthCare Technologies reported strong Q3 earnings, exceeding analysts' expectations with a revenue increase driven by robust demand in imaging and monitoring solutions. The company highlighted its ongoing investments in innovation and digital health, positioning itself for future growth. For investors, these results signal a positive trajectory and reinforce confidence in GEHC's ability to capitalize on market opportunities in the evolving healthcare landscape.

Read full article →

History

People also watch

CI
Cigna Group
--
UNH
UnitedHealth Group Inc.
--
MRK
Merck & Co. Inc.
--
RCKT
Rocket Pharmaceuticals, Inc.
--
ABUS
Arbutus Biopharma Corporation
--